These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9366926)

  • 1. Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients.
    Cogny-Van Weydevelt F; Prud'Homme L; Boucher A; Dandavino R
    Transplant Proc; 1997 Nov; 29(7A):32S-34S. PubMed ID: 9366926
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of OKT3 induction therapy in cadaveric kidney transplantation.
    Alsina J; Bover J; Grinyó JM
    Am J Kidney Dis; 1996 Dec; 28(6):958. PubMed ID: 8957053
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation.
    Shield CF; Jacobs RJ; Wyant S; Das A
    Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

  • 7. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
    Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
    Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis.
    Güz G; Emiroğlu R; Demirhan B; Köseoğlu F; Karakayali H; Bilgin N
    Transplant Proc; 2000 May; 32(3):572-3. PubMed ID: 10812117
    [No Abstract]   [Full Text] [Related]  

  • 11. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Ikemiyashiro D; Ocdol H; Mozes M; Anaise D; Johnson C
    Transplant Proc; 1993 Feb; 25(1 Pt 1):572-4. PubMed ID: 8438419
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic evaluation of immunosuppressive drugs: an empirical example using a secondary database of hospital charges.
    Schommer JC; Pathak DS; Grauer DW
    Transplant Proc; 1996 Apr; 28(2):906. PubMed ID: 8623455
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
    Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
    Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 16. No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients.
    Bemelman FJ; Yong S; Parlevliet KJ; Surachno S; Schellekens PT; ten Berge RJ
    Transplant Proc; 2002 Dec; 34(8):3165-7. PubMed ID: 12493407
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 20. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.